News | Ventricular Assist Devices (VAD) | August 06, 2015

FDA Issues Warning on Left Ventricular Assist Devices

Agency has received reports of pump thrombosis, stroke events and bleeding complications with HeartMate II and HeartWare HVAD devices

FDA, warning, LVADs, left ventricular assist devices, Thoratec, HeartMate II, HeartWare, HVAD

August 6, 2015 — The U.S. Food and Drug Administration (FDA) is alerting healthcare providers, patients and caregivers about serious adverse events associated with left ventricular assist devices (LVADs). These adverse events include an increased rate of pump thrombosis (blood clots inside the pump) with Thoratec’s HeartMate II and a high rate of stroke with the HeartWare HVAD since approval of the devices. The agency is also aware of bleeding complications associated with both devices.

Implantable LVADs help the left ventricle circulate blood throughout the body in patients with advanced heart failure. The devices consist of a blood pump, power pack and controller. The blood pump is implanted inside a patient’s body and attached to the heart’s left ventricle and to the aorta. The power pack and controller are connected to the blood pump and carried by the patient outside the body.

The FDA has received reports and information from a variety of sources indicating an increase in the rate of pump thrombosis events in patients implanted with the HeartMate II. Information also shows that patients are experiencing pump thrombosis events earlier than observed during the clinical trials conducted to support the product’s approvals in 2008 (bridge-to-transplant) and 2010 (destination therapy).

In regards to the HeartWare HVAD, the FDA is aware of recently reported results from a clinical trial designed to evaluate the safety and effectivness of the device when used for the DT indication. Investigators reported 28.7 percent of HVAD patients experienced one or more strokes over two years, compared to 12.1 percent among patients implanted with the control device (HeartMate II).

Both devices have raised concerns about bleeding complications through adverse event reports and information from a variety of sources. The cause of bleeding complications is not fully understood, but is likely due to many different factors. One possible factor may be modification to blood thinning (anticoagulation) therapy in an attempt to lower the risks of pump thrombosis and embolic stroke.

The FDA recommends the following actions for healthcare providers:

Perform a thorough clinical evaluation, assessing the benefit-risk profile of each patient in determining the most appropriate treatment plan and, if necessary, selecting a device;
Consider the risks for pump thrombosis, stroke and bleeding when determining the appropriate therapy for individual patients; and
Review the current device labeling prior to making treatment decisions if you are considering using either of these devices.

Return all explanted LVAD devices and components to their respective manufacturer. In the case of LVAD-related pump thrombosis and other adverse events, manufacturer evaluation of the affected device is critical to better understand the reasons for these adverse events.

The FDA has been working with Thoratec to better understand and explain the increased incidence of pump thrombosis. On Aug. 5, 2014, the FDA approved updated labeling for the HeartMate II that includes the risk of pump thrombosis. Thoratec is currently conducting a prospective, multi-center, non-randomized study designed to assess the incidence of HeartMate II pump thrombosis and to identify the risk factors associated with pump thrombosis events.

Thoratec was purchased by St. Jude Medical in July 2015.

Regarding the HeartWare HVAD, the FDA is concerned about the reported stroke rates, but at this time believes the benefits of using the device continue to outweigh the risk for the currently approved BTT indication. The agency also believes it is appropriate to continue the clinical investigation of this device in the DT population with the careful monitoring procedures currently in place. HeartWare is also currently conducting a prospective, randomized, controlled, un-blinded, multi-center study to assess whether optimal blood pressure management can help lower the incidence of stroke in DT patients implanted with an HVAD.

For more information: www.fda.gov

Related Content

Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
News | Heart Failure | March 29, 2020
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure | March 28, 2020
March 28, 2020 — New data from a sub-analysis of the landmark Phase III...
News | Heart Failure | March 05, 2020
March 5, 2020 — Abbott recently received Breakthrough Device designation from the U.S.
Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA. #heartfailure

Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA. 

Feature | Heart Failure | February 21, 2020 | Dave Fornell, Editor
There are several new tools being added to the clinical armamentarium in the fight against...
Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced care, as show here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. The operator is Nevin Kapur. Photo by Dave Fornell.

Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced hemodynamic support methods, as shown here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. Photo by Dave Fornell.

Feature | Heart Failure | February 20, 2020 | Dave Fornell, Editor
There is no, single magic bullet in heart failure (HF) to easily reduce readmission rates or easily reverse this...
he U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption (IDE) application to start a U.S. early feasibility study (EFS) of its total artificial heart.
News | Heart Failure | February 12, 2020
February 12, 2020 — The U.S.
 Revivant TC
News | Heart Failure | December 18, 2019
December 18, 2019 — BioVentrix, Inc., developer of the first less
 impulse dynamics Optimizer for Heart failure.
News | Heart Failure | December 12, 2019
December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System